在神经退行性疾病中SYK协调神经保护性微质反应
Hannah Ennerfelt1, Elizabeth L Frost2, Daniel A Shapiro2
1Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA; Neuroscience Graduate Program, UVA, Charlottesville, VA 22908, USA; Cell and Molecular Biology Graduate Training Program, UVA, Charlottesville, VA 22908, USA.
Cell
|October 18, 2022
概括
在阿尔茨海默病模型中,氨酸激酶 (SYK) 对微质功能至关重要. 它的删除恶化了粉样β沉积和神经病理,突出显示了SYK在神经保护中的作用.
科学领域:
- 神经科学
- 免疫学
- 细胞生物学
背景情况:
- 在神经退行性疾病中,微细胞在清除神经毒性物质,如粉样β和髓碎片中发挥关键作用.
- 调节有益的微质功能,特别是它们的细胞活动的细胞内信号通路尚未完全理解.
研究的目的:
- 研究 Tyrosine Kinase (SYK) 在微质功能中的作用及其对阿尔茨海默氏症 (AD) 和脱髓化疾病病理学的影响.
- 阐明SYK信号影响微质对神经毒性刺激的分子机制.
主要方法:
- 利用阿尔茨海默病的5xFAD小鼠模型研究微质中向SYK缺失的影响.
- 分析了Aβ沉积,神经病理,认知功能和与疾病相关的小质细胞 (DAM) 的发展.
- 研究了SYK在微细胞和信号通路中的作用,包括在AD和非髓化疾病背景下AKT/GSK3β.
主要成果:
- 在5xFAD小鼠模型中,SYK在微质中的除加剧了Aβ沉积,神经病理和认知缺陷.
- 干扰SYK信号破坏了DAM发育,改变了AKT/ GSK3β信号,并限制了小质Aβ细胞化.
- 发现受体介导的SYK激活会限制Aβ负载,而SYK对微细胞瘤和脱髓化疾病中的DAM获得至关重要.
结论:
- SYK是一种关键的细胞内信号分子,可以调节微质神经保护功能.
- SYK信号传递对于有效的Aβ和髓碎片的微细胞分解以及与疾病相关的微细胞的发展至关重要.
- 这些发现扩大了对神经毒性物质有益的微质反应的先天免疫信号的理解,为神经退行性疾病提供了潜在的治疗点.
相关概念视频
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...